ERAS-601
As of the edition of 20 October 2026, ERAS-601 is a drug known only by a code name: stopped in 2025; acts on PTPN11.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Code name only
- Registered trials
- 5, 1 stopped early
- Disease areas
- Cancer; Bones, joints and muscles; Heart and blood vessels; Inherited and neonatal; Skin and connective tissue; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTPN11 | Tyrosine-protein phosphatase non-receptor type 11 | Q06124 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 3 | 1 | 1 | 1 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Erasca | Lead sponsor of trials | 2020 to now |